OS estimates
| Characteristic . | N . | Event N . | Median survival . | 60 mo OS (95% CI) . | 120 mo OS (95% CI) . | P value∗ . |
|---|---|---|---|---|---|---|
| Overall | 187 | 36 | —† (157, —) | 91% (87%-95%) | 76% (67%-85%) | |
| Stage | 175 | 34 | .073 | |||
| 1-2 | — (170, —) | 94% (88%-100%) | 82% (70%-97%) | |||
| 3-4 | — (134, —) | 88% (81%-95%) | 67% (56%-82%) | |||
| FLIPI score | 139 | 26 | .033 | |||
| 0 | — (—, —) | 100% (100%-100%) | 100% (100%-100%) | |||
| 1 | 171 (157, —) | 94% (87%-100%) | 82% (67%-100%) | |||
| 2 | — (—, —) | 91% (82%-100%) | 75% (58%-96%) | |||
| 3 | — (113, —) | 85% (70%-100%) | 68% (42%-100%) | |||
| 4+ | 106 (84, —) | 78% (60%-100%) | 45% (22%-92%) | |||
| FLIPI risk group | 139 | 26 | .073 | |||
| 0-1 (low) | 171 (170, —) | 95% (89%-100%) | 84% (70%-100%) | |||
| 2 (intermediate) | — (—, —) | 91% (82%-100%) | 75% (58%-96%) | |||
| 3+ (high) | 147 (106, —) | 82% (70%-95%) | 57% (38%-85%) | |||
| Initial management | 177 | 31 | .14 | |||
| Observation | — (157, —) | 94% (88%-99%) | 77% (65%-91%) | |||
| Radiation | — (118, —) | 100% (100%-100%) | 75% (43%-100%) | |||
| Anti-CD20 mAb | 134 (102, —) | 81% (65%-100%) | 57% (33%-99%) | |||
| Chemoimmunotherapy | — (—, —) | 90% (82%-100%) | 86% (75%-99%) |
| Characteristic . | N . | Event N . | Median survival . | 60 mo OS (95% CI) . | 120 mo OS (95% CI) . | P value∗ . |
|---|---|---|---|---|---|---|
| Overall | 187 | 36 | —† (157, —) | 91% (87%-95%) | 76% (67%-85%) | |
| Stage | 175 | 34 | .073 | |||
| 1-2 | — (170, —) | 94% (88%-100%) | 82% (70%-97%) | |||
| 3-4 | — (134, —) | 88% (81%-95%) | 67% (56%-82%) | |||
| FLIPI score | 139 | 26 | .033 | |||
| 0 | — (—, —) | 100% (100%-100%) | 100% (100%-100%) | |||
| 1 | 171 (157, —) | 94% (87%-100%) | 82% (67%-100%) | |||
| 2 | — (—, —) | 91% (82%-100%) | 75% (58%-96%) | |||
| 3 | — (113, —) | 85% (70%-100%) | 68% (42%-100%) | |||
| 4+ | 106 (84, —) | 78% (60%-100%) | 45% (22%-92%) | |||
| FLIPI risk group | 139 | 26 | .073 | |||
| 0-1 (low) | 171 (170, —) | 95% (89%-100%) | 84% (70%-100%) | |||
| 2 (intermediate) | — (—, —) | 91% (82%-100%) | 75% (58%-96%) | |||
| 3+ (high) | 147 (106, —) | 82% (70%-95%) | 57% (38%-85%) | |||
| Initial management | 177 | 31 | .14 | |||
| Observation | — (157, —) | 94% (88%-99%) | 77% (65%-91%) | |||
| Radiation | — (118, —) | 100% (100%-100%) | 75% (43%-100%) | |||
| Anti-CD20 mAb | 134 (102, —) | 81% (65%-100%) | 57% (33%-99%) | |||
| Chemoimmunotherapy | — (—, —) | 90% (82%-100%) | 86% (75%-99%) |